Prudential Financial Inc. lifted its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 4.8% in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 4,404 shares of the biopharmaceutical company’s stock after acquiring an additional 200 shares during the quarter. Prudential Financial Inc.’s holdings in Alnylam Pharmaceuticals were worth $351,000 as of its most recent filing with the SEC.

Several other large investors have also recently modified their holdings of the stock. Vanguard Group Inc. lifted its position in shares of Alnylam Pharmaceuticals by 3.7% in the 1st quarter. Vanguard Group Inc. now owns 5,660,213 shares of the biopharmaceutical company’s stock valued at $290,086,000 after acquiring an additional 200,890 shares in the last quarter. BlackRock Inc. lifted its position in shares of Alnylam Pharmaceuticals by 34,755.2% in the 1st quarter. BlackRock Inc. now owns 4,746,234 shares of the biopharmaceutical company’s stock valued at $243,242,000 after acquiring an additional 4,732,617 shares in the last quarter. Blue Ridge Capital L.L.C. lifted its position in shares of Alnylam Pharmaceuticals by 20.5% in the 1st quarter. Blue Ridge Capital L.L.C. now owns 1,590,000 shares of the biopharmaceutical company’s stock valued at $81,488,000 after acquiring an additional 270,000 shares in the last quarter. Perceptive Advisors LLC lifted its position in shares of Alnylam Pharmaceuticals by 831.4% in the 1st quarter. Perceptive Advisors LLC now owns 1,103,475 shares of the biopharmaceutical company’s stock valued at $56,553,000 after acquiring an additional 985,000 shares in the last quarter. Finally, Janus Capital Management LLC lifted its position in shares of Alnylam Pharmaceuticals by 25.5% in the 1st quarter. Janus Capital Management LLC now owns 649,399 shares of the biopharmaceutical company’s stock valued at $33,280,000 after acquiring an additional 131,969 shares in the last quarter. Institutional investors and hedge funds own 94.25% of the company’s stock.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) opened at 124.20 on Friday. Alnylam Pharmaceuticals, Inc. has a 52 week low of $31.38 and a 52 week high of $126.16. The stock’s 50 day moving average is $99.20 and its 200 day moving average is $76.88. The firm’s market cap is $11.39 billion.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($1.34) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.22) by ($0.12). The business had revenue of $15.93 million during the quarter, compared to the consensus estimate of $23.86 million. Alnylam Pharmaceuticals had a negative return on equity of 45.53% and a negative net margin of 670.81%. The business’s revenue for the quarter was up 82.9% compared to the same quarter last year. During the same period in the prior year, the firm earned ($1.05) EPS. Equities research analysts expect that Alnylam Pharmaceuticals, Inc. will post ($5.20) EPS for the current year.

In other news, President Barry E. Greene sold 76,815 shares of the business’s stock in a transaction on Wednesday, September 20th. The shares were sold at an average price of $100.00, for a total value of $7,681,500.00. Following the sale, the president now owns 165,399 shares of the company’s stock, valued at $16,539,900. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, President Barry E. Greene sold 85,316 shares of the business’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $125.00, for a total transaction of $10,664,500.00. The disclosure for this sale can be found here. Insiders own 4.30% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Alnylam Pharmaceuticals, Inc. (ALNY) Shares Bought by Prudential Financial Inc.” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright law. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2017/10/13/alnylam-pharmaceuticals-inc-alny-shares-bought-by-prudential-financial-inc.html.

Several equities research analysts recently commented on the stock. Ladenburg Thalmann Financial Services set a $90.00 price target on shares of Alnylam Pharmaceuticals and gave the company a “buy” rating in a research report on Monday, July 17th. BidaskClub upgraded shares of Alnylam Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 5th. JMP Securities upped their price target on shares of Alnylam Pharmaceuticals from $101.00 to $128.00 and gave the company an “outperform” rating in a research report on Wednesday, September 20th. J P Morgan Chase & Co restated a “hold” rating on shares of Alnylam Pharmaceuticals in a research report on Monday, June 26th. Finally, Piper Jaffray Companies restated an “overweight” rating and issued a $110.00 price target (down previously from $126.00) on shares of Alnylam Pharmaceuticals in a research report on Thursday, September 7th. Three research analysts have rated the stock with a sell rating, seven have assigned a hold rating and fifteen have assigned a buy rating to the company. Alnylam Pharmaceuticals currently has an average rating of “Hold” and an average price target of $100.80.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Stock Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.